Fax: (319) 335-0191
Article first published online: 20 JAN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 5, pages 1021–1027, 1 March 2009
How to Cite
Lamkin, D. M., Spitz, D. R., Shahzad, M. M. K., Zimmerman, B., Lenihan, D. J., DeGeest, K., Lubaroff, D. M., Shinn, E. H., Sood, A. K. and Lutgendorf, S. K. (2009), Glucose as a prognostic factor in ovarian carcinoma. Cancer, 115: 1021–1027. doi: 10.1002/cncr.24126
Patients provided informed consent before participating in this research.
We gratefully acknowledge the assistance of Heena Maiseri, Kelsey Flaten, and Christiana Taylor in data collection.
See editorial on pages 918-21, this issue.
- Issue published online: 18 FEB 2009
- Article first published online: 20 JAN 2009
- Manuscript Accepted: 4 AUG 2008
- Manuscript Revised: 29 JUL 2008
- Manuscript Received: 14 MAY 2008
- NIH. Grant Numbers: R21CA88293, R01-CA104825, R01-CA100045, P30-CA086862, LAF CF2002-0000832, K07-CA 093512, CA110793, CA199298
- University of Texas M. D. Anderson Ovarian Cancer Spore. Grant Number: P50 CA083639
- ovarian cancer;
- survival rate
Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease-specific survival time and time to recurrence in ovarian cancer patients.
Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease-free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate.
Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2.01; P = .02) and DFI (HR, 2.48; P = .001) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set.
These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma. Cancer 2009. © 2009 American Cancer Society.